Halozyme discloses departure of COO Cortney Caudill
The company reported a senior management change effective June 30, 2026, with Caudill leaving her post as Senior Vice President and Chief Operating Officer.
Halozyme Therapeutics disclosed in an 8-K filed with the Securities and Exchange Commission that on June 30, 2026, the company announced an update to its senior management structure.1
As part of that update, the company announced the departure of Cortney Caudill as the Company's Senior Vice President, Chief Operating Officer.1
In the filing, the company said it would like to thank Ms. Caudill for her contributions during her tenure with the Company.1
The filing did not name a successor for the COO role or provide additional detail on the timing or reasons for the departure.
The 8-K was signed on July 2, 2026 by Darren Snellgrove, identified in the filing as Senior Vice President, Chief Financial Officer.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.